CURRENT APPROACHES IN CANCER IMMUNOTHERAPY

tibbibiyolojiozel-3-2-25kapak

Signaling Pathways in Immunotherapy

Buket ALTINOK GÜNEŞa , Tülin ÖZKANb
aAnkara University Vocational School of Health Services, Depatment of Medical Laboratory Techniques, Ankara, Türkiye
bAnkara University Faculty of Medicine, Department of Medical Biology, Ankara, Türkiye

Altınok Güneş B, Özkan T. Signaling pathways in immunotherapy. Sunguroğlu A, ed. Current Approaches in Cancer Immunotherapy. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.65-72.

ABSTRACT
Immunotherapy is a current technique that is being widely used for cancer patients. Despite the fact that recently implemented cancer immunotherapies have a significant clinical impact, only a similar set of patients respond clinically. Thus, we assessed immunological and oncogenic pathways through which genetic aberrations in cancer cells benefit immune evasion by focusing on the resistance that is intrinsic to immunotherapies. The continuous activation of diverse signaling pathways (e.g. MAPK, Wnt, the cell cycle, etc.) in cancer cells has been found to be able to target multiple immunosuppressive pathways via the production of immunosuppressive cytokines such as IL-10, IL-6, and by causing the immunosuppressive immune cells to include regulatory T cells, dendritic cells, and myeloidderived suppressor cells. In summary, understanding immune evasion mechanisms mediated by tumorintrinsic pathways may help identify novel therapeutic targets to expand the efficacy of cancer immunotherapies.

Keywords: Immune system; immunotherapy; signaling pathways; cancer

Referanslar

  1. Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020;124:109821. [Crossref]
  2. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. [Crossref]  [PubMed]  [PMC]
  3. Hargadon KM. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell Mol Life Sci. 2023;80(2):40. [Crossref]  [PubMed]  [PMC]
  4. Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel). 2021;13(5):1037. [Crossref]  [PubMed]  [PMC]
  5. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5 (5):375-86. [Crossref]
  6. Fish EN, Platanias LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol Cancer Res. 2014; 12(12):1691-703. [Crossref]  [PubMed]  [PMC]
  7. Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016;31:73-81. [Crossref]
  8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024): 1565-70. [Crossref]
  9. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. [Crossref]
  10. Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49. [Crossref]  [PubMed]  [PMC]
  11. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404.e9. [Crossref]  [PubMed]  [PMC]
  12. Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018;50(9):1271-81. [Crossref]  [PubMed]  [PMC]
  13. Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 2022;604(7906):563-70. [Crossref]
  14. Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, et al. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. Cancer Res. 2018;78(2):436-50. [Crossref]  [PubMed]  [PMC]
  15. Kim JY, Choi JK, Jung H. Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin Epigenetics. 2020;12(1):119. [Crossref]  [PubMed]  [PMC]
  16. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162(5):974-86. [Crossref]  [PubMed]  [PMC]
  17. Daskalakis M, Brocks D, Sheng YH, Islam MS, Ressnerova A, Assenov Y, et al. Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. Cell Cycle. 2018;17(7):811-22. [Crossref]  [PubMed]  [PMC]
  18. Snell GD. Studies in histocompatibility. Science. 1981;213(4504):172-8. [Crossref]
  19. Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152-8. [Crossref]  [PubMed]  [PMC]
  20. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2): 100-8.
  21. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172-87. [Crossref]
  22. Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, et al. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 2015;290(44):26562-75. [Crossref]  [PubMed]  [PMC]
  23. Kawazu M, Ueno T, Saeki K, Sax N, Togashi Y, Kanaseki T, et al. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology. 2022;162(3):799-812. [Crossref]
  24. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568. [Crossref]  [PubMed]  [PMC]
  25. Khan AN, Tomasi TB. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res. 2008;40(2):164-78. [Crossref]  [PubMed]  [PMC]
  26. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016;113(21):5999-6004. [Crossref]  [PubMed]  [PMC]
  27. Ren J, Li N, Pei S, Lian Y, Li L, Peng Y, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity. J Clin Invest. 2022;132(8):e153167. [Crossref]  [PubMed]  [PMC]
  28. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, et al. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis. 2016; 7(2):e2120. [Crossref]  [PubMed]  [PMC]
  29. Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, et al. The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. 2021;54(1):132-50.e9. [Crossref]  [PubMed]  [PMC]
  30. Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248. [Crossref]  [PubMed]  [PMC]
  31. Wang X, Waschke BC, Woolaver RA, Chen Z, Zhang G, Piscopio AD, et al. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas. Cancer Immunol Res. 2019;7(8):1318-31. [Crossref]  [PubMed]  [PMC]
  32. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 2001;98(20):11515-20. [Crossref]  [PubMed]  [PMC]
  33. Zhou B, Chen E, Chen J, Zhang J, Zhang N, Chen Z. Overexpression of proteinase inhibitor 9 is associated with poor prognosis in human hepatocellular carcinoma and with proliferation and apoptosis in HepG2 cells in vitro. Int J Clin Exp Pathol. 2019;12(10):3719-27.
  34. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550-8. [Crossref]  [PubMed]  [PMC]
  35. Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, et al. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell. 2020;183(5): 1219-33.e18. [Crossref]  [PubMed]  [PMC]
  36. Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022; 13(1):1606. [Crossref]  [PubMed]  [PMC]
  37. Cucolo L, Chen Q, Qiu J, Yu Y, Klapholz M, Budinich KA, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity. 2022;55(4):671-85.e10. [Crossref]  [PubMed]  [PMC]
  38. Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology. 2015;5(3):e1086862. [Crossref]  [PubMed]  [PMC]
  39. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18(3):139-47. [Crossref]  [PubMed]  [PMC]
  40. Wang Z, Zhao T, Zhang S, Wang J, Chen Y, Zhao H, et al. The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy. Biomark Res. 2021;9(1):68. [Crossref]  [PubMed]  [PMC]
  41. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol. 2012;189(5): 2110-7. [Crossref]
  42. Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, et al. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov. 2019; 9(8):1124-41. [Crossref]  [PubMed]  [PMC]
  43. DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021; 35(5):109071. [Crossref]  [PubMed]  [PMC]
  44. O'Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018;48:91-103. [Crossref]
  45. Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. JAMA Oncol. 2016;2(12):1565-73. [Crossref]
  46. Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 2019;8(5):e1581556. [Crossref]  [PubMed]  [PMC]
  47. Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer. 2022;10(3):e003402. [Crossref]  [PubMed]  [PMC]
  48. Lin YX, Wang Y, Ding J, Jiang A, Wang J, Yu M, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13(599):eaba9772. [Crossref]  [PubMed]  [PMC]
  49. Yang L, Li A, Lei Q, Zhang Y. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol. 2019;12(1):125. [Crossref]  [PubMed]  [PMC]
  50. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103-19.
  51. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al; Cancer Genome Atlas Research Network; Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37.e10.
  52. Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019;9(3):329-41. [Crossref]  [PubMed]  [PMC]
  53. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yet al. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clin Cancer Res. 2019; 25(21):6511-23. [Crossref]
  54. Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-35.
  55. Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-5. [Crossref]  [PubMed]  [PMC]